Literature DB >> 8898076

Differences in specificity for the interactions of stefins A, B and D with cysteine proteinases.

B Lenarcic1, I Krizaj, P Zunec, V Turk.   

Abstract

Four different stefin-type cysteine proteinase inhibitors have been isolated from porcine thymus and skin. Amino acid sequence determination revealed the presence of stefin A and stefin B type inhibitors and two new inhibitors, designated as porcine stefin D1 and stefin D2. Stefin D1 was identified as PLCPI, an inhibitor recently characterized from porcine polymorphonuclear leukocytes [Lenarcic et al. (1993) FEBS Lett. 336, 289-292]. Stefin A is composed of 101 amino acids and has an Mr of 11 391 while stefin B contains 98 amino acids, has an Mr of 11 174 and is N-terminally blocked. All inhibitors were found to be fast-acting inhibitors of papain, cathepsin L and cathepsin S (Ki = 0.009-0.161 nM). Stefins A and B also bind tightly and rapidly to cathepsin H (Ki = 0.027 and 0.069 nM, respectively), while stefins D1 and D2 have been shown to be very poor inhibitors of cathepsin H (Ki = 102-150 nM). The decreased affinity of these inhibitors toward cathepsin B (Ki = 2-1700 nM) was shown to be mainly due to the low second order association rate constants. The presence of a highly negatively charged N-terminus on stefin D1 constitutes a likely structural determinant of inhibitor specificity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898076     DOI: 10.1016/0014-5793(96)00984-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  Role of the single cysteine residue, Cys 3, of human and bovine cystatin B (stefin B) in the inhibition of cysteine proteinases.

Authors:  E Pol; I Björk
Journal:  Protein Sci       Date:  2001-09       Impact factor: 6.725

Review 2.  Molecular background of progressive myoclonus epilepsy.

Authors:  Anna-Elina Lehesjoki
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

3.  Human stefin B normal and patho-physiological role: molecular and cellular aspects of amyloid-type aggregation of certain EPM1 mutants.

Authors:  Mira Polajnar; Slavko Ceru; Nataša Kopitar-Jerala; Eva Zerovnik
Journal:  Front Mol Neurosci       Date:  2012-08-24       Impact factor: 5.639

Review 4.  Biofoams and natural protein surfactants.

Authors:  Alan Cooper; Malcolm W Kennedy
Journal:  Biophys Chem       Date:  2010-06-25       Impact factor: 2.352

5.  Brain inflammation is accompanied by peripheral inflammation in Cstb -/- mice, a model for progressive myoclonus epilepsy.

Authors:  Olesya Okuneva; Zhilin Li; Inken Körber; Saara Tegelberg; Tarja Joensuu; Li Tian; Anna-Elina Lehesjoki
Journal:  J Neuroinflammation       Date:  2016-11-28       Impact factor: 8.322

Review 6.  Journey of cystatins from being mere thiol protease inhibitors to at heart of many pathological conditions.

Authors:  Anas Shamsi; Bilqees Bano
Journal:  Int J Biol Macromol       Date:  2017-04-23       Impact factor: 6.953

7.  The first structure in a family of peptidase inhibitors reveals an unusual Ig-like fold.

Authors:  Daniel J Rigden; Qingping Xu; Yuanyuan Chang; Ruth Y Eberhardt; Robert D Finn; Neil D Rawlings
Journal:  F1000Res       Date:  2013-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.